5-aminosalicylic acid

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC, Sheba Medical Center, Asian Institute of Gastroenterology, India

Conditions

Colitis, UlcerativeHIV InfectionsUlcerative Colitis

Phase 1

Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients

CompletedNCT00069498

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 1999-10-31Target: 14Updated: 2007-05-25

Phase 3

Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)

TerminatedNCT00984568

Merck Sharp & Dohme LLCColitis, Ulcerative

Start: 2009-11-30End: 2012-03-31Updated: 2017-04-13

Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis

CompletedNCT01320436

Sheba Medical CenterUlcerative Colitis

Start: 2011-07-31End: 2014-10-31Updated: 2016-02-12

Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis

Asian Institute of Gastroenterology, IndiaUlcerative Colitis

Start: 2016-02-29Target: 50Updated: 2016-02-23

Related Papers

Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis

Journal of Clinical Gastroenterology2020-09-0452 citations

Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.

2015-02-24237 citations